Ep. 40: Why CAN SLIM Hedge Fund Manager Jim Roppel Is Bullish In the Current Market
Investing With IBD
00:00
The Rise and Fall of Biotechs
The breadth of the market getting into biotechs is fantastic. I personally dislike them greatly, but that's a lie. It has great earnings. Look, earnings matter. The only area of froth I can see is that these earning list stocks have been allowed to go public and inflate. And so you're seeing the rails coming, you're seeing some retail coming, biotechs too.
Transcript
Play full episode
